Article Text

Novel treatment (new drug/intervention; established drug/procedure in new situation)
Treatment of Buerger disease (thromboangiitis obliterans) with bosentan: a case report
  1. Joaquin De Haro,
  2. Aurora Florez,
  3. Jose Luis Fernandez,
  4. Francisco Acin
  1. Hospital Universitario Getafe, Angiology and Vascular Surgery, Carretera de Toledo Km 12500, Getafe, 28905, Spain
  1. Joaquin De Haro, deharojoaquin{at}yahoo.es

Summary

Buerger disease (thromboangiitis obliterans) is a non-atherosclerotic segmental inflammatory disease strongly associated with tobacco use, and it affects small and medium-sized blood vessels in the upper and lower extremities. The only known treatment for this disease is complete discontinuation of tobacco use. This report describes the case history of a woman with Buerger disease treated with the oral dual endothelin receptor antagonist bosentan. It is believed that this is the first description in the literature of this use for bosentan.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests: none.

  • Patient consent: Patient/guardian consent was obtained for publication.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.